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a b s t r a c t
The ﬁrst-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regi-
mens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of
SustainedVirological Response inbothnaive and treatment-experiencedpatientswith chronic genotype-
1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly
variable and results from the combination of multiple factors related to the characteristics of patient,eywords:
oceprevir
irrhosis
epatitis C
egylated-interferon
viral status and liver disease.
The recommendations presented are promoted by the Italian Association for the Study of the Liver,
with the aim to help the physician in the decision-making process as well as to manage patients during
treatment with triple therapy.
Gastibavirin
elaprevir
© 2013 Editrice
Boceprevir (BOC) and Telaprevir (TVR) are the ﬁrst two direct
ntiviral agents (DAA) registered for the treatment of patients with
hronic genotype 1 hepatitis C virus (HCV) infection. Both, admin-
stered with Peg-interferon alpha (Peg-IFN) and Ribavirin (RBV),
ave been proven to be effective in increasing the rate of Sustained
irological Response (SVR) in naive and experienced chronic HCV
enoptype-1 patients [1–8]. However, at the individual level, the
herapeutic advantage of a triple therapy regimen is highly vari-
ble and results from the combination of multiple factors including
atient’s characteristics, viral parameters, and liver disease sever-
ty.These Recommendations for the use of triple therapy (Peg-
FN+Ribavirin +ﬁrst-generation Protease Inhibitor) in genotype 1
hronic hepatitis C, promoted by the Italian Association for the
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Study of the Liver (AISF), are meant to provide physicians with
practical indications on the decision-making process as well as on
management of patients during treatmentwith Protease Inhibitors.
The recommendations were divided into three levels of evi-
dence according to the GRADE system: A (high), B (medium) and
C (low), together with 2 recommendation levels: 1 (strong) and 2
(weak).
Members of the AISF Coordinating Committee and of the AISF
Consulting Committee on New Antiviral Hepatitis C drugs con-
tributed to the document. The ﬁnal draft was then submitted to
the evaluation of external experts and the text modiﬁed according
their suggestion and comments.
1. Naive patients
1.1. Selection of naive patients as candidates for triple therapy
treatment
The availability of BOC- and TVR-based triple therapy does not
change the current indications for hepatitis C treatment, which
should be evaluated in all patients,with the exception of thosewith
decompensated cirrhosis or other absolute contraindications to the
use of Peg-IFN and RBV [9,10].Therapy should be considered primarily in patients with signif-
icant ﬁbrosis (METAVIR≥ F2), with priority for those with severe
ﬁbrosis (METAVIR F3) and compensated cirrhosis (METAVIR F4),
Child–Pugh A class.
Ltd. All rights reserved.
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For patients with no or mild ﬁbrosis (METAVIR F0–F1), the indi-
ation to treatment must be assessed on a case by case basis, taking
nto account the risk of disease progression aswell as extra-hepatic
anifestations related to HCV, potential side effects, patient moti-
ation and high likelihood of the forthcoming availability of new
AAs with higher therapeutic efﬁcacy and better tolerability, espe-
ially with the impending arrival of IFN-free regimens.
.2. Decision-making algorithm
The current knowledge calls for a personalized approach to hep-
titis C therapy, which must be assessed according to multiple
ariables that may inﬂuence each patient’s case:
. risk of disease progression
. likelihood of therapeutic success
. risk/beneﬁt ratio of treatment
The risk of disease progression, as the mean estimated time to
evelop cirrhosis or clinical complications of cirrhosis (clinically
igniﬁcant portal hypertension, liver decompensation and hepato-
ellular carcinoma), is mostly correlated with ﬁbrosis stage. Thus,
he assessment of hepatic ﬁbrosis is mandatory, since treatment is
ore needed over a brief period time in patients with evidence of
evere ﬁbrosis or compensated cirrhosis (F3–F4) [11,12]. Appendix
focuses on the methods used to evaluate hepatic ﬁbrosis (see
upplementary materials).
The risk of disease progression is also inﬂuenced by patient-
peciﬁc features (age and age at infection, sex, race, genetics), viral
arameters (viral load, genotype and heterogeneity), co-factors of
iver disease (alcohol use, diabetes, insulin-resistance, obesity) and
o-infections with other viruses [13].
Indication for treatment is also expressed according to the
ikelihood of therapeutic success. This is inﬂuenced by treatment
chedule, age, disease stage (the likelihood of therapeutic success is
nversely related to disease stage), IL28B genotype (its relevance is
elated to antiviral drug potency, thus lower in triple vs. dual ther-
py) and the virological proﬁle (viral load, genotype and, in case
f triple treatment, viral sub-type by virtue of the lower SVR rates
nd higher likelihood to develop resistance for the genotype 1a)
1,6,7,14–17].
The treatment risk/beneﬁt ratio ismainlybound to the incidence
nd severity of the side effects, which are signiﬁcantly increased
ith the triple therapy, mostly in patients with advanced ﬁbrosis
r cirrhosis [4,6].
Even though the role of positive predictive factors (low viral
eplication rate, CC homozygosis for the IL28B rs12979860 poly-
orphism,mildﬁbrosis) hasbeendescribedboth fordual and triple
herapy, no pre-treatment parameter is able to predict SVR with a
iagnostic accuracy higher than 90%.
At present, Rapid Virological Response (RVR), deﬁned as unde-
ectable HCV RNA at week 4 of Peg-IFN+RBV therapy, is the most
ccurate predictive factor of SVR [18,19]. It follows that 4 weeks
f dual therapy for assessing RVR is a valuable mean to identify
hose patients with high IFN-responsiveness and high probability
o achieve SVR. In such cases, it is reasonable to continue treatment
ith dual therapy without adding the Protease Inhibitor, avoiding
he risk of additional side effects. Nevertheless, it should be con-
idered that the likelihood of reaching RVR decreases progressively
rom 34–23% in patients without advanced ﬁbrosis, to 21–11% in
ubjects with advanced ﬁbrosis/cirrhosis [20,21] and that the pos-
tive predictive power of RVR is reduced in patients with severe
brosis, and it does not exceed 50% in cirrhotic patients [21].
The initial 4-week course of dual therapy is also helpful to
eﬁne the risk/beneﬁt ratio of triple therapy in patients with more
dvanced disease and a lower likelihood to achieve SVR. Indeed, inease 46 (2014) 18–24 19
cirrhotic patients treated with BOC, the reduction of HCV RNA<1
log after the 4-week lead-in with Peg-IFN+RBV is an unfavourable
prognostic indicator of SVR [6]. There is currently no information
regarding the use of TVR after a 4-week dual therapy in naive
patients.
Finally, regardless of the DAA used, the 4-week initial dual
therapy may be used as a “tolerability test” for the purpose of iden-
tifying the patients, mostly represented by those with an advanced
disease, who develop adverse reactions with dual therapy and
who will likely not be able to sustain a triple therapy course (see
paragraph 5).
Recommendations
1. The availability of triple therapy in naive patients does not
change the indications for hepatitis C treatment, whichmust
beevaluated inall patients, except thosewithdecompensated
cirrhosis (A1).
2. Patients with severe ﬁbrosis (F3) or compensated cirrhosis
(F4) in Child–Pugh class A are the main candidates to BOC or
TVR triple based therapy. Those patients have higher clinical
priority for treatment, to prevent the progression of liver dis-
ease (A1). In some, mostly non-cirrhotic patients, continuing
treatment with dual therapy upon accomplishing RVR may
be considered in thepresence of favourable predictive factors
(e.g., IL28B CC or low viral load) and/or high risk of develop-
ing side effects (B2). In cirrhotic patients (F4) with viral load
reduction <1LogUI/mL after the ﬁrst 4 weeks of lead-in with
dual therapy, addition of BOC should be assessed on a case by
case basis, given the lower likelihood to reach SVR (B1).
3. In patients with moderate ﬁbrosis (F2), triple therapy is
indicated, while, in those with mild or no ﬁbrosis (F0–F1),
indication is more controversial and must be assessed indi-
vidually, taking into account the low short-mid term risk
of disease progression, extra-hepatic manifestations of HCV
infection, potential side effects, patient motivation and
future therapeutic options with more effective drugs with
fewer side effects (B1). In patients with F0–F2 ﬁbrosis, an ini-
tial 4-week lead-in with Peg-IFN+RBV allows to customize
treatmentbasedonon-treatment virological response. If RVR
ispresent it is appropriate to containdual therapy, as the like-
lihoodof SVR is veryhigh. If RVR isnotobtained, patientswith
moderate ﬁbrosis (F2) should continue with a triple ther-
apy regimen; in patients with no or mild ﬁbrosis (F0–F1), the
choice between stopping antiviral treatment or continuing
with triple therapy should be assessed individually (B1).
4. Patients in which treatment is deferred must be monitored
periodically according to their disease stage, in order to iden-
tify progression of liver disease and thus reconsider the need
for treatment (A1).
2. Patients with failure to previous dual therapy
(experienced)
2.1. Selection of “experienced” patients as candidates for triple
therapy
BOC- or TVR-based triple therapy signiﬁcantly increases SVR
rates in patients with previous failure to dual therapy [3,5,8,22].
Thus, experienced patients are suitable candidates for triple ther-
apy regimens.
However, even in this setting, the indicationmust beweighed in
each patient considering in mind the risk of disease progression in
the short-term, likelihood of therapeutic success, risk/beneﬁt ratio
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f treatment and the possible alternative therapeutic options to
ecome available in the short/mid-term.
.2. Decision-making algorithm
The likelihood of SVR with triple therapy varies remarkably
epending on the non-response proﬁle to previous dual therapy
higher in relapsers, lower in null responders and intermediate in
artial responders) and the extent of virological response (at least
logUI/mol drop of serum HCV RNA levels) after 4 weeks of dual
reatment with Peg-IFN+RBV before adding DAA. Additional pre-
icting factors from post hoc analyses are the stage of liver ﬁbrosis
nd the viral subtype [3,8,23,24].
According to previous response proﬁle and virological response,
VR rate with BOC was higher in patients with HCV RNA decline
1 logUI/mL both among partial responders (61% vs. 37%) and
elapsers (81% vs. 37%) [3]. In case of TVR treatment, SVR rate
as higher in patients with HCV RNA decline >1 logUI/mL in null
esponders (54% vs. 15%) and relapsers (94% vs. 62%), while it was
asically similar among partial responders (59% vs. 56%) [23].
Basedon the abovementioneddata, relapsers are very good can-
idates to triple treatment regimens, given the high likelihood of
eaching SVR. The same may also apply to partial responders, even
hough response rates are lower and inﬂuenced, to a variable extent
ith the two DAAs, by ﬁbrosis stage and sensitivity to IFN. In these
atients, for BOC regimens a viral load decline <1 logUI/mL after 4
eeks of dual therapy provides an additional tool to determine the
ikelihood of therapeutic response at the individual level [3,22].
In null responders, the therapeutic advantage of triple therapy
ith BOC and TVR is generally lower. In this setting, a reduction
1 logUI/mL of serum HCV RNA after 4 weeks of dual therapy
llows to select a subgroup of patients whose potential response
ate appears to be quite low, particularly when associated with
ther negative predictors (high viral load, advanced ﬁbrosis, geno-
ype 1a), reducing the therapeutic advantage vs. dual therapy to a
imited or even arguably inexistent level.
In real-life practice many patients who previously failed to
espond to treatment with Peg-IFN+RBV do not have an exact
ecord of the type of failure. In this setting, an initial 4-week course
f Peg-IFN+RBV is useful to predict the efﬁcacy of triple therapy.
Finally, patients with virological breakthrough during a pre-
ious treatment with Peg-IFN+RBV (reappearance of HCV RNA
uring therapy, after achieving undetectability) can be assimilated
o relapsers, since they have shown some degree of sensitivity to
FN.
Recommendations
. BOC or TVR triple therapy is currently the reference treat-
ment for patients with previous Peg-IFN+RBV failure (A1).
Similarly to naive patients, the indication to therapy should
be assessed considering the risk of liver disease progres-
sion and consequently priority to treatment, likelihood of
response, potential treatment sideeffects, patientmotivation
and future therapeutic options (A1).
. In relapsers, triple therapy is strongly indicated in the pres-
ence of severe ﬁbrosis (F3) or compensated cirrhosis (F4) in
Child–Pugh class A; it is indicated in patients with moderate
ﬁbrosis (F2), while it should be discussed on a case by case
basis for patients with no or mild ﬁbrosis (F0–F1) (A1).
. In partial responders, triple therapy is strongly indicated in
the presence of severe ﬁbrosis (F3) or compensated cirrho-
sis (F4) in Child–Pugh class A; it is indicated in patients with
moderate ﬁbrosis (F2), while it should be discussed a case
by case basis for patients with no or mild ﬁbrosis (F0–F1)ease 46 (2014) 18–24
(B1). A 4-week lead-in phase with Peg-IFN+RBV contributes
to deﬁne the likelihood of SVR in patients receiving BOC (B1).
4. In null responders, the indication to triple therapy must
be carefully assessed considering the risk/beneﬁt ratio. The
evaluation of serum HCV RNA decline during the ﬁrst 4
weeks of dual therapy is particularly useful to identify those
patients with low likelihood of SVR (B1). If the reduction
is <1 logUI/mL, the decision to add a DAA and continue
a triple therapy regimen must be re-assessed individually
by weighting the poor response likelihood and the risk of
disease progression with the therapeutic “urgency” (B1).
According to the criteria of the Italian Drug Agency (AIFA),
no reimbursement for triple therapy is provided in patients
with F0–F2 ﬁbrosis presenting a <1 log reduction in viral load
after 4 weeks of dual therapy.
5. Patients inwhich treatment isdeferredmustbe followedover
time in order to rule out disease progression, which would
determine a re-assessment for treatment indication (A1).
6. In case of unknown response proﬁle to previous dual ther-
apy, an initial 4-week course of Peg-IFN+RBV would help to
predict the efﬁcacy of a triple treatment regimen (B2).
3. Therapeutic schedules
Therapeutic schedules of BOC or TVR triple therapy regimens
have been allowed by regulatory Agencies as shown in Appendix
2 (see Supplementary materials). Naive patients without cirrhosis
and relapsers may follow a response-guided schedule with both
DAAs, while patients with cirrhosis and non-responders need to
receive a longer ﬁxed regimen (see Supplementary materials).
4. Stopping rules during treatment and viral resistance
Based on registration studies, the European Medicines Agency
(EMA) suggests to discontinue treatment with BOC in case of HCV
RNA≥100UI/mLatweek12ordetectableHCVRNAatweek24 [25];
treatment with TVR in case of HCV RNA≥1000UI/mL at weeks 4 or
12 or detectable HCV RNA at week 24 [26].
However, a recent post hoc analysis has shown that none of the
patients BOC-treated with <1 log HCV RNA reduction vs. baseline
after a 4-week lead-in and <3 log reduction after 4 weeks of triple
therapy obtained SVR (negative predictive value: 100%) [27].
This data, if conﬁrmed in larger cohorts, will arguably lead to a
change in the BOC discontinuation stopping criteria. Pending this,
for patients in triple therapy with BOC it is advisable to perform
an additional serum HCV RNA assay at week 8, for the purpose of
considering an early discontinuation, especially in subjects display-
ing poor treatment tolerance.
For TVR therapy, it may be advisable to adopt a serum HCV RNA
threshold of 100UI/mL at weeks 4 and 12 as a cut-off for drug
discontinuation for the purpose of containing the risk of select-
ing resistant viral strains, particularly when TVR is started after 4
weeksofdual therapy.However, if triple therapywithTVR is started
from the beginning, we still suggest to follow the EMA indications
until stronger evidence will support more stringent discontinua-
tion criteria [26].
To guarantee an adequate virological monitoring, HCV RNA
assays should have a lower detection limit of 15UI/mL and the
results should be available within 3 working days. Rapid availabil-
ity of HCV RNA results is needed to promptly apply the stopping
rules, thus limiting the risk of developing viral resistance.At present, the clinicalmeaning of selection of resistant variants
is controversial. If therapeutic failure with BOC- and TVR-based
therapies is invariably associated with the selection of resistant
viral strains, studies with prolonged follow-up have shown that
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he variants progressively decline over time with a restoration of
he “wild type” population [28–30]. Furthermore, the impact of
esistant variants on the efﬁcacy of future therapeutic approaches
s uncertain.
Recommendations
. According to the indications approved by the EMA, triple
therapy with BOC must be discontinued in case of HCV RNA
≥100UI/mL at week 12 or detectable at week 24; triple ther-
apy with TVR in case of HCV RNA ≥1000UI/mL at weeks 4 or
12 or detectable at week 24 (B1).
. In patients receiving BOC with HCV RNA decrease <1 log after
the 4-week lead-in, an additional HCV RNA dosing should be
performed at week 8 and, in case of a <3 log reduction vs.
baseline, it is acceptable to stop treatment (B2).
. In patients receiving TVR after 4 weeks of dual therapy,
it could be reasonable to stop TVR in case of HCV RNA
≥100UI/mL at weeks 8 or 12, in order to avoid selection of
resistant viral strains (C2).
. Determination of BOC and TVR viral resistance should be
restricted to patients treated within research protocols (B1).
. Side effect management in patients with cirrhosis
A main concern with the use of triple therapy is the higher
ncidence of adverse events, particularly serious in patients with
dvanced disease, and responsible for early treatment discontinu-
tion (11–25% of the cases in registration studies). It is therefore
andatory, before starting therapy, to perform comprehensive
atient “counselling”. Patients must be informed of the risk, type
nd severity of treatment-related adverse events, on the need of
ight clinical and laboratory monitoring and on management of
dverse events.
Management of anaemia, skin rash and ano-rectal discomfort
re reported in Appendix 3 (see Supplementary material). Speciﬁc
ndications for cirrhotic patients, those with higher risk of devel-
ping severe adverse reactions, are provided below.
Registration studies with both DAAs enrolled a limited num-
er of cirrhotic patients. Further information on the safety of these
rugs are currently available thanks to increased access to BOC
nd TVR regimens, showing that the incidence of adverse events,
ncluding those requiring hospitalization, is signiﬁcantly higher
han reported in previous studies. It has been also reported that
he monitoring and management of side effects requires a great
ffort by physicians [31–33].
Besides anaemia which often requires erythropoietin (Epo)
herapy and blood transfusion, cirrhotic patients are also predis-
osed to develop bacterial infections and liver decompensation,
hich were also responsible for treatment deaths, with a reported
ortality of 1–3% [31–33].
A very recent analysis of the French Compassionate Use
f Protease Inhibitors in Viral C Cirrhosis (CUPIC) identiﬁed a
eries of clinical/laboratory variables associated with a higher
isk of developing severe clinical complications and death, which
ncludes: age >65 years, serum albumin <3.5 g/dL, thrombocy-
openia <100,000/mmc, clinically signiﬁcant portal hypertension,
revious ascites, functional impairment or digestive bleeding,
ecline of albuminemia during therapy, and lack of lead-in with
ual therapy. Moreover, patients with albumin levels <3.5 g/dL and
latelet <100,000/mmc present a risk of severe adverse events
nd death above 40% [31]. Similarly, a recent monocentric Ger-
an prospective study, has shown that patients with a platelet
evel <110,000/mmc and Child–Pugh score >5 have a higher risk
f hospitalization [32].ease 46 (2014) 18–24 21
However, preliminary data from 609 patients (20% Italian) in
the Expanded Access Programme (EAP) to TVR for patients with
advanced ﬁbrosis (F3) or cirrhosis (F4) seem to provide more
encouraging data on treatment tolerability, reporting a lower
incidence of severe anaemia, bacterial infections, liver decom-
pensation, hospitalization and mortality [33]. A rather accurate
and consistent patient selection (only those with compensated
cirrhosis and platelets >90,000/mmc were enrolled) seems to be
one of the possible explanations for the better safety proﬁle in the
EAP compared to the CUPIC compassionate trial.
Recommendations
1. The management of BOC- and TVR-based triple therapy in
patients with cirrhosis is particularly difﬁcult and requires
a great commitment from physicians (A1).
2. Patients with compensated cirrhosis are a heterogeneous
population. Several clinical/laboratory variables (e.g., combi-
nation of platelet count <100,000/mmc and serum albumin
levels <3.5 g/dL)may be used to identify thosewith the higher
risk for severe adverse events and death (B2).
3. An initial 4-week dual therapy before the addition of the DAA
can be used as tolerability test to identify subjects with low
tolerance to Peg-IFN and/or RBV and therefore potentially
unsuitable to sustain a triple therapy regimen (C1).
4. Patients with cirrhosis receiving triple therapy should be
strictly monitored in order to promptly diagnose and man-
age adverse reactions (A1). Besides the typical side effects
related to triple therapy (anaemia, skin rash), special atten-
tion must be devoted to the risk of infectious diseases and
hepatic decompensation (A1).
5. Given the above reasons, in the presence of risk factors for
severe adverse events, cirrhotic patients should be treated
in centres with considerable expertise in management of
antiviral therapy in patients with advanced liver disease. The
enrolment of these patients in clinical trials using second
generation antiviral drugs with fewer side effects should be
encouraged (B1).
6. Special populations
6.1. Patients with HIV/HCV co-infections
As a result of the high efﬁcacy of the current antiretroviral treat-
ments, hepatitis C has become an important cause ofmorbidity and
mortality in patients with HIV/HCV co-infection [34,35]. In these
patients, liver disease progression is faster and the response rate to
dual therapy lower, with a SVR rate equal to 15–29% for genotype
1 [36].
The concerns regarding possible drug-to-drug interactions,
related to the common metabolic pathway through cytochrome
CYP3A4 of BOC and TVR with antiretroviral drugs, contraindicated
the inclusion of HIV patients in DAA registration studies.
However, phase II studies and other reported series have
shown a similar efﬁcacy and safety proﬁles for triple therapy in
HIV/HCV and HCV-monoinfected patients [37,38]. Nevertheless,
the incidence of anaemia was higher with both drugs and, in
the TVR group, skin rash (approximately 56%) caused early drug
discontinuation in 5–7% of cases [37,38].Recommendations
1. Hepatitis C treatment should be considered in all patients
with HIV/HCV co-infection (A1).
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. Triple therapy in patients is indicated in naive or relapser
patients with signiﬁcant ﬁbrosis (≥F2) (B1). Given the limited
data in non responder patients (partial or null responders), in
this setting the indication to triple therapy shouldbeassessed
on a case by case basis, taking into account the individual
risk/beneﬁt ratio (B1).
. Patients should be treated in centres with speciﬁc expertise,
with strict clinical and laboratory monitoring. Enrollment in
study protocols should be encouraged (B1).
. Triple therapy is currently not recommended for patients
with mild or no ﬁbrosis (F0–F1), due to reduced tolerability
of co-infected patients to Peg-IFN+RBV and the impending
availability of interferon-free regimens with better efﬁcacy
and safety proﬁles (B1).
.2. Liver transplant recipients
Hepatitis C infection recurs invariably after liver transplantation
nd evolves rapidly: about 30% of patients develop cirrhosis within
years and, in those with cirrhosis, about 50% progress to liver fail-
re within 1 year [39]. Treatment with Peg-IFN+RBV is indicated
n patients with signiﬁcant ﬁbrosis (METAVIR≥ F2), although SVR
ates are lower than those observed in immunocompetent patients
40].
Preliminary results regarding the use of triple therapy with BOC
nd TVR have been reported in several series including a total of
bout 250patients,mainly non responsive to previous dual therapy
41–43].
As a whole, the data available today indicate that undetectable
erumHCV RNA after 3months of treatment is achieved in 40–90%,
promising result considering the positive predictive value, which
n early viral response implies for the achievement of SVR [41–43].
In the post-transplant setting, the main concern in DAA use
efers to the interaction with Cyclosporin and Tacrolimus, as BOC
nd particularly TVR are responsible for greatly increasing the
erum levels of both immunosuppressors [44,45].
As far as tolerability is concerned, the most frequent reported
ide effect was anaemia, treated by reducing RBV dosage, use of
poetin in 50–100% of cases and blood transfusion in 50% of cases.
ther severe adverse events included neutropenia, skin rash, renal
unction worsening and bacterial infections. Overall, 25% of the
atients prematurely discontinued treatment due to side effects
r viral breakthrough; several cases of death were also reported
41–43].
Recommendations
. Triple therapy with BOC or TVR should be considered for
recurrent hepatitis C in liver transplant recipients, in case of
at least moderate ﬁbrosis (≥F2) (B1).
. Even in absence of available data, transplant recipients who
develop a ﬁbrosing cholestatic hepatitis can be treated with
triple therapy, due to therapeutic urgency (C1).
. In patients receiving BOC and TVR, Cyclosporin and
Tacrolimus plasma levels should be closely monitored in
order to maintain immunosuppression within the thera-
peutic range through dose adjustments (A1). Switch from
Tacrolimus to Cyclosporin may be also considered due to
lower interaction of the latter with BOC and TVR (B2).
. Liver transplant recipients receiving triple therapy should
be rigorously monitored to promptly diagnose and manage
adverse reactions (A1).
. For the above mentioned reasons, triple therapy with BOC
and TVR should be managed by hepatologists with speciﬁcease 46 (2014) 18–24
expertise in antiviral therapy in close connection with trans-
plant centres (C1).
6.3. Patients with cryoglobulinemia
In a preliminary experience, triple therapy with BOC in 24
non responder patients to dual therapy with advanced ﬁbrosis or
cirrhosis and symptomatic mixed cryoglobulinemia produced a
rapid cryocrit negativization in 19 cases and purpura and arthral-
gia remission during treatment, even though SVR rate was lower
compared to the control group without cryoglobulinemia [46].
Recommendations
1. Due to limited available experience, patients with symp-
tomatic cryoglobulinemia should be treated with triple
therapy only in centres with speciﬁc expertise in the man-
agement of extra-hepatic syndromes (B1).
2. DAA triple based regimens are not recommended for patients
with severe cryoglobulinemia (B1).
7. Drug-to-drug interactions
BOC and TVR are metabolized through cytochromes P450 3A4
and 3A5 (CYP3A4/5). Moreover, both Protease Inhibitors are strong
inhibitors of the same P450 cytochrome family, which accounts
for over 30% of total liver P450 cytochrome. According to this, the
risk of interactions with drugs, with the same metabolic pathways,
is a main concern in clinical practice [47].
Recommendations
Before starting a BOC or TVR triple therapy, a detailed phar-
macological history ismandatory to avoid potential dangerous
drug-to-drug interactions (A1). Moreover, during triple ther-
apy, physicians are required to refer to speciﬁc periodically
updated databases (e.g., www.hep-druginteractions.org) and
search for alternative drugs not metabolized by CYP3As (A1).
8. Conclusions
The advent of the ﬁrst-generation Protease Inhibitors BOC
and TVR, administered with Peg-IFN and RBV, has signiﬁcantly
improved the SVR rate both in naive and experienced patients with
chronic genotype 1 hepatitis C.
Nevertheless, their use is partly offset by the high incidence of
side effects and the complexity of their management requiring a
great effort by clinical staff, as well as by the lower efﬁcacy in
difﬁcult to treat-patients (cirrhotics and non-responders to Peg-
IFN+RBV). Taken together, all these factors can result in limited
access to therapy, particularly in patients with more advanced dis-
ease.
Moreover, the expectation for new antiviral agents, which will
be available in the next years and appear to be safer, simpler
and more effective, introduces the possibility to defer the therapy,
sometimesmaking thedecision to treat thepatientwith the current
triple regimens even more complex.
At present, hepatologists have the ethical obligation to share
with the patient both risks and beneﬁts related to the current treat-
ment as well as to its deferral, taking into account the limitations
in accurately staging liver disease and in predicting clinical pro-
gression. Furthermore, physicians and patients must be aware that
for many promising agents in the HCV pipeline there is no pre-
dictable time to market or reimbursement in many parts of the
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he near future to provide recommendations for customizing treat-
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